Researchers at the Mount Sinai Tisch Cancer Center have discovered that a hidden folate deficiency may be the cause of severe anemia in some patients treated with PARP inhibitors, a widely used class of targeted cancer therapies. This underrecognized condition can be easily treated with folic acid supplements, potentially helping patients avoid blood transfusions, hospitalizations, and interruptions to their cancer treatment.

Key Takeaways

  • Severe anemia in some PARP inhibitor patients is linked to a previously overlooked folate deficiency.
  • Routine screening for folate levels could identify at-risk patients early.
  • Folic acid treatment may reduce the need for blood transfusions and hospitalizations, allowing cancer therapy to continue without interruption.

Understanding PARP Inhibitors

PARP inhibitors are a class of targeted drugs used to treat certain cancers, including ovarian, breast, pancreatic, and prostate cancers. They work by blocking the PARP enzyme, which cancer cells rely on to repair DNA damage. This treatment has become a standard option for patients with BRCA mutations and other DNA repair deficiencies. While generally well tolerated, PARP inhibitors can cause side effects, including fatigue and low blood counts. Severe anemia, however, has not been fully understood until now.

The Discovery of a Folate Connection

In a study published in the journal Blood Red Cells & Iron, Mount Sinai researchers examined a group of patients on PARP inhibitors who developed severe anemia that could not be explained by common causes. They found that many of these patients had low folate levels, a vitamin essential for red blood cell production. The folate deficiency was not captured by standard blood tests because it was “functional” rather than absolute, meaning the body could not properly use the folate available. Once researchers identified the issue, they treated patients with folic acid supplements, and anemia improved in most cases.

Implications for Cancer Care

This finding has immediate practical implications. According to the researchers, routine screening of folate levels in patients starting PARP inhibitors could flag those at risk for severe anemia. Early intervention with folic acid may prevent the need for blood transfusions and hospital stays, which can delay cancer treatment and affect quality of life. The study’s lead author noted that this is a simple, low-cost intervention that could be easily integrated into standard oncology practice.

Next Steps for Research and Practice

The team at Mount Sinai plans to conduct larger prospective studies to confirm these findings and develop screening guidelines. They also encourage oncologists to consider folate deficiency when patients on PARP inhibitors develop unexplained anemia. Because folic acid is a widely available supplement, the change in practice could be rapid. However, patients should not start taking folic acid without consulting their doctor, as it may interact with other aspects of treatment.

Frequently Asked Questions

What are PARP inhibitors?

PARP inhibitors are targeted cancer drugs that block an enzyme called PARP, which helps repair DNA in cancer cells. They are used to treat several types of cancer, especially in patients with BRCA mutations. Common PARP inhibitors include olaparib, niraparib, rucaparib, and talazoparib.

How is folate deficiency detected in these patients?

Standard blood tests measure serum folate, but this may miss a functional folate deficiency. Researchers now recommend specific tests that look at red blood cell folate or other markers of folate activity. Any patient on a PARP inhibitor who develops unexplained anemia should be evaluated for folate issues.

Can folic acid treatment interfere with cancer therapy?

In this study, folic acid supplements did not appear to interfere with the anticancer effects of PARP inhibitors. However, patients should always discuss any supplements with their oncology team before starting them. The researchers emphasize that the folic acid used was a standard vitamin supplement, not a high dose.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.